Long-Term Cost-Effectiveness of Using Glucagon-Like Peptide 1 Receptor Agonists (GLP-1RAs) for Preventing Type 2 Diabetes (T2D) in U.S. Adults with Prediabetes and Obesity—A Simulation Study

Related

• SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs

  Diabetes & Vascular Disease Research · 4 Oct 2026

• GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk

  Diabetes, Obesity & Metabolism · 4 Oct 2026

• SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes

  Clinical Journal of the American Society of Nephrology · 4 Oct 2026

• Survodutide reduces weight in adults with diabetes and obesity

  The New England Journal of Medicine · 4 Oct 2026